Today's Date
Belimumab and Rituximab for Primary Membranous Nephropathy
(
REBOOT
)
ITN Protocol #:
ITN080AI
Branded Name:
REBOOT
Treatment Protocol #:
Therapeutic Area:
Autoimmune Disease
Current Status:
Enrollment
Summary:
A double-blind, randomized, placebo-controlled trial of belimumab and rituximab compared to rituximab alone for the treatment of primary membranous nephropathy
Clinical Operations Associate Director
Clinical Operations Manager
ITN Biologist
ITN Clinical Trial Physician
NIAID Project Manager
Rho Scientist
Study Personnel:
